- Home
- ABLV vs ANTX Comparison
ABLV vs ANTX Comparison
Compare ABLV & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- ANTX
- Stock Information
- Founded
- ABLV 2015
- ANTX 2017
- Country
- ABLV China
- ANTX United States
- Employees
- ABLV N/A
- ANTX N/A
- Industry
- ABLV
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- ABLV
- ANTX Health Care
- Exchange
- ABLV Nasdaq
- ANTX Nasdaq
- Market Cap
- ABLV 32.9M
- ANTX 34.4M
- IPO Year
- ABLV N/A
- ANTX 2022
- Fundamental
- Price
- ABLV $0.65
- ANTX $1.05
- Analyst Decision
- ABLV
- ANTX Buy
- Analyst Count
- ABLV 0
- ANTX 1
- Target Price
- ABLV N/A
- ANTX $2.00
- AVG Volume (30 Days)
- ABLV 9.4K
- ANTX 73.8K
- Earning Date
- ABLV 12-19-2025
- ANTX 11-12-2025
- Dividend Yield
- ABLV N/A
- ANTX N/A
- EPS Growth
- ABLV N/A
- ANTX N/A
- EPS
- ABLV 0.05
- ANTX N/A
- Revenue
- ABLV $114,319,869.00
- ANTX N/A
- Revenue This Year
- ABLV N/A
- ANTX N/A
- Revenue Next Year
- ABLV N/A
- ANTX N/A
- P/E Ratio
- ABLV $14.37
- ANTX N/A
- Revenue Growth
- ABLV N/A
- ANTX N/A
- 52 Week Low
- ABLV $0.55
- ANTX $1.01
- 52 Week High
- ABLV $1.77
- ANTX $1.68
- Technical
- Relative Strength Index (RSI)
- ABLV 39.23
- ANTX 42.85
- Support Level
- ABLV $0.61
- ANTX $1.05
- Resistance Level
- ABLV $0.70
- ANTX $1.12
- Average True Range (ATR)
- ABLV 0.06
- ANTX 0.05
- MACD
- ABLV -0.00
- ANTX -0.00
- Stochastic Oscillator
- ABLV 33.16
- ANTX 36.00
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.